Download PDF
Semin Neurol 2018; 38(03): 355-370
DOI: 10.1055/s-0038-1660520
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Autoimmune Neurologic Diseases in Children

Michael Sweeney
1   Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky
› Author Affiliations
Further Information

Publication History

Publication Date:
16 July 2018 (online)

    Permissions and Reprints

Abstract

Autoimmune diseases of the nervous system in children are composed of a heterogeneous group of rare disorders that can affect the central or peripheral nervous system at any level. Presentations may occur in children of any age and are typically acute or subacute in onset. Consideration of an autoimmune process as the etiology of neurologic diseases in children is important, as it may lead to early initiation of immunotherapy and an improvement in long-term neurologic outcomes. The developing nervous and immune systems in children create unique challenges in diagnosis and treatment of these rare diseases. In this review, autoimmune diseases affecting the brain, spinal cord, nerve roots, peripheral nerves, neuromuscular junction, and muscle in children are described.

Keywords

pediatric autoimmune neurology - autoimmune encephalitis - NMDA receptor encephalitis - pediatric neuromyelitis optica - acute disseminated encephalomyelitis

Financial Disclosure

MS has received speaking and consulting fees for Genentech and Novartis.


 

  • References

  • 1 Glaser CA, Gilliam S, Schnurr D. , et al; California Encephalitis Project, 1998-2000. In search of encephalitis etiologies: diagnostic challenges in the California Encephalitis Project, 1998-2000. Clin Infect Dis 2003; 36 (06) 731-742
    CrossrefPubMedGoogle Scholar
  • 2 Graus F, Titulaer MJ, Balu R. , et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15 (04) 391-404
    CrossrefPubMedGoogle Scholar
  • 3 Chang K, Frankovich J, Cooperstock M. , et al; PANS Collaborative Consortium. Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference. J Child Adolesc Psychopharmacol 2015; 25 (01) 3-13
    CrossrefPubMedGoogle Scholar
  • 4 Hesselmark E, Bejerot S. Biomarkers for diagnosis of Pediatric Acute Neuropsychiatric Syndrome (PANS) - Sensitivity and specificity of the Cunningham Panel. J Neuroimmunol 2017; 312: 31-37
    CrossrefPubMedGoogle Scholar
  • 5 Berger I, Castiel Y, Dor T. Paediatric Hashimoto encephalopathy, refractory epilepsy and immunoglobulin treatment - unusual case report and review of the literature. Acta Paediatr 2010; 99 (12) 1903-1905
    CrossrefPubMedGoogle Scholar
  • 6 Bektas Ö, Yılmaz A, Kendirli T, Sıklar Z, Deda G. Hashimoto encephalopathy causing drug-resistant status epilepticus treated with plasmapheresis. Pediatr Neurol 2012; 46 (02) 132-135
    CrossrefPubMedGoogle Scholar
  • 7 Castro-Gago M, Gómez-Lado C, Maneiro-Freire M, Eirís-Puñal J, Bravo-Mata M. Hashimoto encephalopathy in a preschool girl. Pediatr Neurol 2010; 42 (02) 143-146
    CrossrefPubMedGoogle Scholar
  • 8 Goenka A, Jain V, Nariai H, Spiro A, Steinschneider M. Extended clinical spectrum of anti-N-methyl-d-aspartate receptor encephalitis in children: a case series. Pediatr Neurol 2017; 72: 51-55
    CrossrefPubMedGoogle Scholar
  • 9 Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10 (01) 63-74
    CrossrefPubMedGoogle Scholar
  • 10 Titulaer MJ, McCracken L, Gabilondo I. , et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12 (02) 157-165
    CrossrefPubMedGoogle Scholar
  • 11 Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 2012; 54 (07) 899-904
    CrossrefPubMedGoogle Scholar
  • 12 Armangue T, Titulaer MJ, Málaga I. , et al; Spanish Anti-N-methyl-D-Aspartate Receptor (NMDAR) Encephalitis Work Group. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr 2013; 162 (04) 850-856.e2
    CrossrefPubMedGoogle Scholar
  • 13 Wright S, Hacohen Y, Jacobson L. , et al. N-methyl-D-aspartate receptor antibody-mediated neurological disease: results of a UK-based surveillance study in children. Arch Dis Child 2015; 100 (06) 521-526
    CrossrefPubMedGoogle Scholar
  • 14 Florance NR, Davis RL, Lam C. , et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009; 66 (01) 11-18
    CrossrefPubMedGoogle Scholar
  • 15 Sartori S, Nosadini M, Cesaroni E. , et al. Paediatric anti-N-methyl-D-aspartate receptor encephalitis: the first Italian multicenter case series. Eur J Paediatr Neurol 2015; 19 (04) 453-463
    CrossrefPubMedGoogle Scholar
  • 16 Armangue T, Leypoldt F, Málaga I. , et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 2014; 75 (02) 317-323
    CrossrefPubMedGoogle Scholar
  • 17 Yushvayev-Cavalier Y, Nichter C, Ramirez-Zamora A. Possible autoimmune association between herpes simplex virus infection and subsequent anti-N-methyl-d-aspartate receptor encephalitis: a pediatric patient with abnormal movements. Pediatr Neurol 2015; 52 (04) 454-456
    CrossrefPubMedGoogle Scholar
  • 18 Titulaer MJ, Leypoldt F, Dalmau J. Antibodies to N-methyl-D-aspartate and other synaptic receptors in choreoathetosis and relapsing symptoms post-herpes virus encephalitis. Mov Disord 2014; 29 (01) 3-6
    CrossrefPubMedGoogle Scholar
  • 19 Scott O, Richer L, Forbes K. , et al. Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis: an unusual cause of autistic regression in a toddler. J Child Neurol 2014; 29 (05) 691-694
    CrossrefPubMedGoogle Scholar
  • 20 Dalmau J, Gleichman AJ, Hughes EG. , et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7 (12) 1091-1098
    CrossrefPubMedGoogle Scholar
  • 21 Suppiej A, Nosadini M, Zuliani L. , et al. Plasma exchange in pediatric anti-NMDAR encephalitis: a systematic review. Brain Dev 2016; 38 (07) 613-622
    CrossrefPubMedGoogle Scholar
  • 22 Byrne S, Walsh C, Hacohen Y. , et al. Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome. Neurol Neuroimmunol Neuroinflamm 2015; 2 (04) e130
    CrossrefPubMedGoogle Scholar
  • 23 Matricardi S, Patrini M, Freri E. , et al. Cognitive and neuropsychological evolution in children with anti-NMDAR encephalitis. J Neurol 2016; 263 (04) 765-771
    CrossrefPubMedGoogle Scholar
  • 24 McKeon GL, Scott JG, Spooner DM. , et al. Cognitive and social functioning deficits after anti-N-methyl-D-aspartate receptor encephalitis: an exploratory case series. J Int Neuropsychol Soc 2016; 22 (08) 828-838
    CrossrefPubMedGoogle Scholar
  • 25 Dhamija R, Renaud DL, Pittock SJ. , et al. Neuronal voltage-gated potassium channel complex autoimmunity in children. Pediatr Neurol 2011; 44 (04) 275-281
    CrossrefPubMedGoogle Scholar
  • 26 Hacohen Y, Singh R, Rossi M. , et al. Clinical relevance of voltage-gated potassium channel–complex antibodies in children. Neurology 2015; 85 (11) 967-975
    CrossrefPubMedGoogle Scholar
  • 27 Akman CI, Patterson MC, Rubinstein A, Herzog R. Limbic encephalitis associated with anti-GAD antibody and common variable immune deficiency. Dev Med Child Neurol 2009; 51 (07) 563-567
    CrossrefPubMedGoogle Scholar
  • 28 Haberlandt E, Bast T, Ebner A. , et al. Limbic encephalitis in children and adolescents. Arch Dis Child 2011; 96 (02) 186-191
    CrossrefPubMedGoogle Scholar
  • 29 Sweeney M, Sweney M, Soldán MM, Clardy SL. Antineuronal nuclear autoantibody type 1/anti-Hu-associated opsoclonus myoclonus and epilepsia partialis continua: case report and literature review. Pediatr Neurol 2016; 65: 86-89
    CrossrefPubMedGoogle Scholar
  • 30 Meyer JJ, Bulteau C, Adamsbaum C, Kalifa G. Paraneoplastic encephalomyelitis in a child with neuroblastoma. Pediatr Radiol 1995; 25 (Suppl. 01) S99-S101
    PubMedGoogle Scholar
  • 31 Yeo KK, Walter AW, Miller RE, Dalmau J. Rituximab as potential therapy for paraneoplastic cerebellar degeneration in pediatric Hodgkin disease. Pediatr Blood Cancer 2012; 58 (06) 986-987
    CrossrefPubMedGoogle Scholar
  • 32 Bernal F, Shams'ili S, Rojas I. , et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003; 60 (02) 230-234
    CrossrefPubMedGoogle Scholar
  • 33 Lancaster E. CNS syndromes associated with antibodies against metabotropic receptors. Curr Opin Neurol 2017; 30 (03) 354-360
    CrossrefPubMedGoogle Scholar
  • 34 Kunstreich M, Kreth JH, Oommen PT. , et al. Paraneoplastic limbic encephalitis with SOX1 and PCA2 antibodies and relapsing neurological symptoms in an adolescent with Hodgkin lymphoma. Eur J Paediatr Neurol 2017; 21 (04) 661-665
    CrossrefPubMedGoogle Scholar
  • 35 Petit-Pedrol M, Armangue T, Peng X. , et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014; 13 (03) 276-286
    CrossrefPubMedGoogle Scholar
  • 36 Joshi DD, Anderson PM, Matsumoto J. , et al. Metastatic chondroblastoma with elevated creatine kinase and paraneoplastic neurologic autoimmunity. J Pediatr Hematol Oncol 2003; 25 (11) 900-904
    CrossrefPubMedGoogle Scholar
  • 37 Tardieu M, Banwell B, Wolinsky JS, Pohl D, Krupp LB. Consensus definitions for pediatric MS and other demyelinating disorders in childhood. Neurology 2016; 87 (09) (Suppl. 02) S8-S11
    CrossrefPubMedGoogle Scholar
  • 38 Krupp LB, Banwell B, Tenembaum S. ; International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007; 68 (16) (Suppl. 02) S7-S12
    CrossrefPubMedGoogle Scholar
  • 39 Erol I, Ozkale Y, Alkan O, Alehan F. Acute disseminated encephalomyelitis in children and adolescents: a single center experience. Pediatr Neurol 2013; 49 (04) 266-273
    CrossrefPubMedGoogle Scholar
  • 40 Pellegrino P, Carnovale C, Perrone V. , et al. Acute disseminated encephalomyelitis onset: evaluation based on vaccine adverse events reporting systems. PLoS One 2013; 8 (10) e77766
    CrossrefPubMedGoogle Scholar
  • 41 Murthy SN, Faden HS, Cohen ME, Bakshi R. Acute disseminated encephalomyelitis in children. Pediatrics 2002; 110 (2, Pt 1): e21
    CrossrefPubMedGoogle Scholar
  • 42 Pohl D, Tenembaum S. Treatment of acute disseminated encephalomyelitis. Curr Treat Options Neurol 2012; 14 (03) 264-275
    CrossrefPubMedGoogle Scholar
  • 43 Burton KLO, Williams TA, Catchpoole SE, Brunsdon RK. Long-term neuropsychological outcomes of childhood onset acute disseminated encephalomyelitis (ADEM): a meta-analysis. Neuropsychol Rev 2017; 27 (02) 124-133
    CrossrefPubMedGoogle Scholar
  • 44 Brilot F, Dale RC, Selter RC. , et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009; 66 (06) 833-842
    CrossrefPubMedGoogle Scholar
  • 45 Baumann M, Sahin K, Lechner C. , et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 2015; 86 (03) 265-272
    CrossrefPubMedGoogle Scholar
  • 46 Lennon VA, Wingerchuk DM, Kryzer TJ. , et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364 (9451): 2106-2112
    CrossrefPubMedGoogle Scholar
  • 47 Weinshenker BG, Wingerchuk DM, Vukusic S. , et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006; 59 (03) 566-569
    CrossrefPubMedGoogle Scholar
  • 48 Matiello M, Lennon VA, Jacob A. , et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008; 70 (23) 2197-2200
    CrossrefPubMedGoogle Scholar
  • 49 Collongues N, Marignier R, Zéphir H. , et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology 2010; 74 (09) 736-742
    CrossrefPubMedGoogle Scholar
  • 50 Chitnis T, Ness J, Krupp L. , et al. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology 2016; 86 (03) 245-252
    CrossrefPubMedGoogle Scholar
  • 51 McKeon A, Lennon VA, Lotze T. , et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008; 71 (02) 93-100
    CrossrefPubMedGoogle Scholar
  • 52 Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, Hunter JV. Spectrum of pediatric neuromyelitis optica. Pediatrics 2008; 122 (05) e1039-e1047
    CrossrefPubMedGoogle Scholar
  • 53 Banwell B, Tenembaum S, Lennon VA. , et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008; 70 (05) 344-352
    CrossrefPubMedGoogle Scholar
  • 54 Wingerchuk DM, Banwell B, Bennett JL. , et al; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85 (02) 177-189
    CrossrefPubMedGoogle Scholar
  • 55 Collongues N, Marignier R, Zéphir H. , et al. Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology 2010; 75 (12) 1084-1088
    CrossrefPubMedGoogle Scholar
  • 56 Gao J, Pan W, Zhang H. Features of neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies. JAMA Neurol 2014; 71 (07) 923-924
    CrossrefPubMedGoogle Scholar
  • 57 Rostásy K, Mader S, Hennes EM. , et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler 2013; 19 (08) 1052-1059
    CrossrefPubMedGoogle Scholar
  • 58 Benseler SM, Silverman E, Aviv RI. , et al. Primary central nervous system vasculitis in children. Arthritis Rheum 2006; 54 (04) 1291-1297
    CrossrefPubMedGoogle Scholar
  • 59 Benseler SM, deVeber G, Hawkins C. , et al. Angiography-negative primary central nervous system vasculitis in children: a newly recognized inflammatory central nervous system disease. Arthritis Rheum 2005; 52 (07) 2159-2167
    CrossrefPubMedGoogle Scholar
  • 60 Hutchinson C, Elbers J, Halliday W. , et al. Treatment of small vessel primary CNS vasculitis in children: an open-label cohort study. Lancet Neurol 2010; 9 (11) 1078-1084
    CrossrefPubMedGoogle Scholar
  • 61 Granata T, Gobbi G, Spreafico R. , et al. Rasmussen's encephalitis: early characteristics allow diagnosis. Neurology 2003; 60 (03) 422-425
    CrossrefPubMedGoogle Scholar
  • 62 Bien CG, Urbach H, Deckert M. , et al. Diagnosis and staging of Rasmussen's encephalitis by serial MRI and histopathology. Neurology 2002; 58 (02) 250-257
    CrossrefPubMedGoogle Scholar
  • 63 Rogers SW, Andrews PI, Gahring LC. , et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994; 265 (5172): 648-651
    CrossrefPubMedGoogle Scholar
  • 64 Wiendl H, Bien CG, Bernasconi P. , et al. GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis. Neurology 2001; 57 (08) 1511-1514
    CrossrefPubMedGoogle Scholar
  • 65 Bien CG, Granata T, Antozzi C. , et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 2005; 128 (Pt 3): 454-471
    CrossrefPubMedGoogle Scholar
  • 66 Pradeep K, Sinha S, Mahadevan A. , et al. Clinical, electrophysiological, imaging, pathological and therapeutic observations among 18 patients with Rasmussen's encephalitis. J Clin Neurosci 2016; 25: 96-104
    CrossrefPubMedGoogle Scholar
  • 67 Granata T, Fusco L, Gobbi G. , et al. Experience with immunomodulatory treatments in Rasmussen's encephalitis. Neurology 2003; 61 (12) 1807-1810
    CrossrefPubMedGoogle Scholar
  • 68 Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs 2005; 22 (01) 8-19
    CrossrefPubMedGoogle Scholar
  • 69 Pranzatelli MR, Travelstead AL, Tate ED. , et al. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology 2004; 62 (09) 1526-1532
    CrossrefPubMedGoogle Scholar
  • 70 Antunes NL, Khakoo Y, Matthay KK. , et al. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol 2000; 22 (04) 315-320
    CrossrefPubMedGoogle Scholar
  • 71 Pranzatelli MR, Tate ED, Wheeler A. , et al. Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia. Pediatr Neurol 2002; 27 (05) 384-387
    CrossrefPubMedGoogle Scholar
  • 72 Panzer JA, Anand R, Dalmau J, Lynch DR. Antibodies to dendritic neuronal surface antigens in opsoclonus myoclonus ataxia syndrome. J Neuroimmunol 2015; 286: 86-92
    CrossrefPubMedGoogle Scholar
  • 73 Pranzatelli MR, Tate ED, Travelstead AL. , et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2006; 28 (09) 585-593
    CrossrefPubMedGoogle Scholar
  • 74 Pranzatelli MR, Tate ED, Swan JA. , et al. B cell depletion therapy for new-onset opsoclonus-myoclonus. Mov Disord 2010; 25 (02) 238-242
    CrossrefPubMedGoogle Scholar
  • 75 Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011; 36 (02) 123-133
    CrossrefPubMedGoogle Scholar
  • 76 Hahn AF. Guillain-Barré syndrome. Lancet 1998; 352 (9128): 635-641
    CrossrefPubMedGoogle Scholar
  • 77 Korinthenberg R, Schessl J, Kirschner J. Clinical presentation and course of childhood Guillain-Barré syndrome: a prospective multicentre study. Neuropediatrics 2007; 38 (01) 10-17
    Article in Thieme ConnectPubMedGoogle Scholar
  • 78 Jones HR. Childhood Guillain-Barré syndrome: clinical presentation, diagnosis, and therapy. J Child Neurol 1996; 11 (01) 4-12
    CrossrefPubMedGoogle Scholar
  • 79 Delanoe C, Sebire G, Landrieu P, Huault G, Metral S. Acute inflammatory demyelinating polyradiculopathy in children: clinical and electrodiagnostic studies. Ann Neurol 1998; 44 (03) 350-356
    CrossrefPubMedGoogle Scholar
  • 80 Yikilmaz A, Doganay S, Gumus H, Per H, Kumandas S, Coskun A. Magnetic resonance imaging of childhood Guillain-Barre syndrome. Childs Nerv Syst 2010; 26 (08) 1103-1108
    CrossrefPubMedGoogle Scholar
  • 81 Singhi SC, Jayshree M, Singhi P, Banerjee S, Prabhakar S. Intravenous immunoglobulin in very severe childhood Guillain-Barré syndrome. Ann Trop Paediatr 1999; 19 (02) 167-174
    CrossrefPubMedGoogle Scholar
  • 82 El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study. Crit Care 2011; 15 (04) R164
    CrossrefPubMedGoogle Scholar
  • 83 McLeod JG, Pollard JD, Macaskill P, Mohamed A, Spring P, Khurana V. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999; 46 (06) 910-913
    CrossrefPubMedGoogle Scholar
  • 84 Nevo Y, Topaloglu H. 88th ENMC international workshop: childhood chronic inflammatory demyelinating polyneuropathy (including revised diagnostic criteria), Naarden, The Netherlands, December 8-10, 2000. Neuromuscul Disord 2002; 12 (02) 195-200
    CrossrefPubMedGoogle Scholar
  • 85 Nevo Y, Pestronk A, Kornberg AJ. , et al. Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology 1996; 47 (01) 98-102
    CrossrefPubMedGoogle Scholar
  • 86 Korinthenberg R. Chronic inflammatory demyelinating polyradiculoneuropathy in children and their response to treatment. Neuropediatrics 1999; 30 (04) 190-196
    Article in Thieme ConnectPubMedGoogle Scholar
  • 87 McMillan HJ, Kang PB, Jones HR, Darras BT. Childhood chronic inflammatory demyelinating polyradiculoneuropathy: combined analysis of a large cohort and eleven published series. Neuromuscul Disord 2013; 23 (02) 103-111
    CrossrefPubMedGoogle Scholar
  • 88 Querol L, Rojas-García R, Diaz-Manera J. , et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm 2015; 2 (05) e149
    CrossrefPubMedGoogle Scholar
  • 89 Burnor E, Yang L, Zhou H. , et al. Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies. Neurology 2018; 90 (01) e31-e38
    CrossrefPubMedGoogle Scholar
  • 90 D'Amico A, Catteruccia M, De Benedetti F. , et al. Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy. Eur J Paediatr Neurol 2012; 16 (03) 301-303
    CrossrefPubMedGoogle Scholar
  • 91 McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology 2010; 34 (03) 171-183
    CrossrefPubMedGoogle Scholar
  • 92 Castro D, Derisavifard S, Anderson M, Greene M, Iannaccone S. Juvenile myasthenia gravis: a twenty-year experience. J Clin Neuromuscul Dis 2013; 14 (03) 95-102
    CrossrefPubMedGoogle Scholar
  • 93 Anlar B, Senbil N, Köse G, Değerliyurt A. Serological follow-up in juvenile myasthenia: clinical and acetylcholine receptor antibody status of patients followed for at least 2 years. Neuromuscul Disord 2005; 15 (05) 355-357
    CrossrefPubMedGoogle Scholar
  • 94 Skjei KL, Lennon VA, Kuntz NL. Muscle specific kinase autoimmune myasthenia gravis in children: a case series. Neuromuscul Disord 2013; 23 (11) 874-882
    CrossrefPubMedGoogle Scholar
  • 95 Pitt M. Neurophysiological strategies for the diagnosis of disorders of the neuromuscular junction in children. Dev Med Child Neurol 2008; 50 (05) 328-333
    CrossrefPubMedGoogle Scholar
  • 96 Golnik KC, Pena R, Lee AG, Eggenberger ER. An ice test for the diagnosis of myasthenia gravis. Ophthalmology 1999; 106 (07) 1282-1286
    CrossrefPubMedGoogle Scholar
  • 97 Liew WK, Powell CA, Sloan SR. , et al. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA Neurol 2014; 71 (05) 575-580
    CrossrefPubMedGoogle Scholar
  • 98 Stieglbauer K, Topakian R, Schäffer V, Aichner FT. Rituximab for myasthenia gravis: three case reports and review of the literature. J Neurol Sci 2009; 280 (1-2): 120-122
    CrossrefPubMedGoogle Scholar
  • 99 Nikolic DM, Nikolic AV, Lavrnic DV, Medjo BP, Ivanovski PI. Childhood-onset myasthenia gravis with thymoma. Pediatr Neurol 2012; 46 (05) 329-331
    CrossrefPubMedGoogle Scholar
  • 100 Gui M, Luo X, Lin J. , et al. Long-term outcome of 424 childhood-onset myasthenia gravis patients. J Neurol 2015; 262 (04) 823-830
    CrossrefPubMedGoogle Scholar
  • 101 Sauce D, Larsen M, Fastenackels S. , et al. Evidence of premature immune aging in patients thymectomized during early childhood. J Clin Invest 2009; 119 (10) 3070-3078
    CrossrefPubMedGoogle Scholar
  • 102 Mendez EP, Lipton R, Ramsey-Goldman R. , et al; NIAMS Juvenile DM Registry Physician Referral Group. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003; 49 (03) 300-305
    CrossrefPubMedGoogle Scholar
  • 103 Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 1995; 34 (08) 732-736
    CrossrefPubMedGoogle Scholar
  • 104 Pachman LM, Lipton R, Ramsey-Goldman R. , et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum 2005; 53 (02) 166-172
    CrossrefPubMedGoogle Scholar
  • 105 Reed AM, Pachman L, Ober C. Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1 *0501. Hum Immunol 1991; 32 (04) 235-240
    CrossrefPubMedGoogle Scholar
  • 106 Miller FW, Chen W, O'Hanlon TP. , et al; Myositis Genetics Consortium. Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. Genes Immun 2015; 16 (07) 470-480
    CrossrefPubMedGoogle Scholar
  • 107 Mamyrova G, O'Hanlon TP, Monroe JB. , et al; Childhood Myositis Heterogeneity Collaborative Study Group. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum 2006; 54 (12) 3979-3987
    CrossrefPubMedGoogle Scholar
  • 108 Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292 (07) 344-347
    CrossrefPubMedGoogle Scholar
  • 109 McCann LJ, Juggins AD, Maillard SM. , et al; Juvenile Dermatomyositis Research Group. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)–clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006; 45 (10) 1255-1260
    CrossrefPubMedGoogle Scholar
  • 110 Aggarwal R, Loganathan P, Koontz D, Qi Z, Reed AM, Oddis CV. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford) 2017; 56 (02) 247-254
    CrossrefPubMedGoogle Scholar
  • 111 Enders FB, Bader-Meunier B, Baildam E. , et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 2017; 76 (02) 329-340
    CrossrefPubMedGoogle Scholar
  • 112 Ruperto N, Pistorio A, Oliveira S. , et al; Paediatric Rheumatology International Trials Organisation (PRINTO). Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet 2016; 387 (10019): 671-678
    CrossrefPubMedGoogle Scholar
  • 113 Oddis CV, Reed AM, Aggarwal R. , et al; RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65 (02) 314-324
    CrossrefPubMedGoogle Scholar
  • 114 Martin N, Krol P, Smith S. , et al; Juvenile Dermatomyositis Research Group. A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. Rheumatology (Oxford) 2011; 50 (01) 137-145
    CrossrefPubMedGoogle Scholar
  • 115 Hanissian AS, Masi AT, Pitner SE, Cape CC, Medsger Jr TA. Polymyositis and dermatomyositis in children: an epidemiologic and clinical comparative analysis. J Rheumatol 1982; 9 (03) 390-394
    PubMedGoogle Scholar
  • 116 Rider LG, Miller FW. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 1997; 23 (03) 619-655
    CrossrefPubMedGoogle Scholar
  • 117 Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008; 371 (9631): 2201-2212
    CrossrefPubMedGoogle Scholar
  • 118 Rider LG. The heterogeneity of juvenile myositis. Autoimmun Rev 2007; 6 (04) 241-247
    CrossrefPubMedGoogle Scholar
  • 119 McKeon A, Robinson MT, McEvoy KM. , et al. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol 2012; 69 (02) 230-238
    CrossrefPubMedGoogle Scholar
  • 120 Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 1990; 322 (22) 1555-1560
    CrossrefPubMedGoogle Scholar
  • 121 Clardy SL, Lennon VA, Dalmau J. , et al. Childhood onset of stiff-man syndrome. JAMA Neurol 2013; 70 (12) 1531-1536
    CrossrefPubMedGoogle Scholar
  • 122 Pineles D, Valente A, Warren B, Peterson MG, Lehman TJ, Moorthy LN. Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus. Lupus 2011; 20 (11) 1187-1192
    CrossrefPubMedGoogle Scholar
  • 123 Sibbitt Jr WL, Brandt JR, Johnson CR. , et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002; 29 (07) 1536-1542
    PubMedGoogle Scholar
  • 124 Malleson PN, Fung MY, Rosenberg AM. The incidence of pediatric rheumatic diseases: results from the Canadian Pediatric Rheumatology Association Disease Registry. J Rheumatol 1996; 23 (11) 1981-1987
    PubMedGoogle Scholar
  • 125 The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42 (04) 599-608
    CrossrefPubMedGoogle Scholar
  • 126 Postal M, Lapa AT, Reis F, Rittner L, Appenzeller S. Magnetic resonance imaging in neuropsychiatric systemic lupus erythematosus: current state of the art and novel approaches. Lupus 2017; 26 (05) 517-521
    CrossrefPubMedGoogle Scholar
  • 127 Groot N, de Graeff N, Avcin T. , et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis 2017; 76 (11) 1788-1796
    CrossrefPubMedGoogle Scholar
  • 128 Matsui Y, Takenouchi T, Narabayashi A, Ohara K, Nakahara T, Takahashi T. Childhood Sjögren syndrome presenting as acute brainstem encephalitis. Brain Dev 2016; 38 (01) 158-162
    CrossrefPubMedGoogle Scholar
  • 129 Rojas-Rodriguez J, Garcia-Carrasco M, Ramirez ES. , et al. Optic neuropathy in a child with primary Sjögren's syndrome. Rev Rhum Engl Ed 1998; 65 (05) 355-357
    PubMedGoogle Scholar
  • 130 Gerraty RP, McKelvie PA, Byrne E. Aseptic meningoencephalitis in primary Sjögren's syndrome. Response to plasmapheresis and absence of CNS vasculitis at autopsy. Acta Neurol Scand 1993; 88 (04) 309-311
    PubMedGoogle Scholar
  • 131 Nagahiro S, Mantani A, Yamada K, Ushio Y. Multiple cerebral arterial occlusions in a young patient with Sjögren's syndrome: case report. Neurosurgery 1996; 38 (03) 592-595 , discussion 595
    PubMedGoogle Scholar
  • 132 Lieberman SM. Childhood Sjögren syndrome: insights from adults and animal models. Curr Opin Rheumatol 2013; 25 (05) 651-657
    CrossrefPubMedGoogle Scholar
  • 133 Avcin T, Cimaz R, Rozman B. ; Ped-APS Registry Collaborative Group. The Ped-APS Registry: the antiphospholipid syndrome in childhood. Lupus 2009; 18 (10) 894-899
    CrossrefPubMedGoogle Scholar
  • 134 Avcin T, Cimaz R, Silverman ED. , et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics 2008; 122 (05) e1100-e1107
    CrossrefPubMedGoogle Scholar
  • 135 Aguiar CL, Soybilgic A, Avcin T, Myones BL. Pediatric antiphospholipid syndrome. Curr Rheumatol Rep 2015; 17 (04) 27
    CrossrefPubMedGoogle Scholar
  • 136 Honnorat J, Didelot A, Karantoni E. , et al. Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology 2013; 80 (24) 2226-2232
    CrossrefPubMedGoogle Scholar
  • 137 Langer JE, Lopes MB, Fountain NB. , et al. An unusual presentation of anti-Hu-associated paraneoplastic limbic encephalitis. Dev Med Child Neurol 2012; 54 (09) 863-866
    CrossrefPubMedGoogle Scholar
  • 138 Aravamuthan BR, Sánchez Fernández I, Zurawski J, Olson H, Gorman M, Takeoka M. Pediatric anti-Hu-associated encephalitis with clinical features of Rasmussen encephalitis. Neurol Neuroimmunol Neuroinflamm 2015; 2 (05) e150
    CrossrefPubMedGoogle Scholar
  • 139 Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol 2001; 50 (03) 301-311
    CrossrefPubMedGoogle Scholar
  • 140 Pettingill P, Kramer HB, Coebergh JA. , et al. Antibodies to GABAA receptor α1 and γ2 subunits: clinical and serologic characterization. Neurology 2015; 84 (12) 1233-1241
    CrossrefPubMedGoogle Scholar
  • 141 Spatola M, Petit-Pedrol M, Simabukuro MM. , et al. Investigations in GABAA receptor antibody-associated encephalitis. Neurology 2017; 88 (11) 1012-1020
    CrossrefPubMedGoogle Scholar
  • 142 Höftberger R, Titulaer MJ, Sabater L. , et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 2013; 81 (17) 1500-1506
    CrossrefPubMedGoogle Scholar
  • 143 Kruer MC, Hoeftberger R, Lim KY. , et al. Aggressive course in encephalitis with opsoclonus, ataxia, chorea, and seizures: the first pediatric case of γ-aminobutyric acid type B receptor autoimmunity. JAMA Neurol 2014; 71 (05) 620-623
    CrossrefPubMedGoogle Scholar
  • 144 Gleichman AJ, Panzer JA, Baumann BH, Dalmau J, Lynch DR. Antigenic and mechanistic characterization of anti-AMPA receptor encephalitis. Ann Clin Transl Neurol 2014; 1 (03) 180-189
    CrossrefPubMedGoogle Scholar
  • 145 Kim SY, Choi SA, Ryu HW. , et al. Screening autoimmune anti-neuronal antibodies in pediatric patients with suspected autoimmune encephalitis. J Epilepsy Res 2014; 4 (02) 55-61
    CrossrefPubMedGoogle Scholar
  • 146 Suleiman J, Wright S, Gill D. , et al. Autoantibodies to neuronal antigens in children with new-onset seizures classified according to the revised ILAE organization of seizures and epilepsies. Epilepsia 2013; 54 (12) 2091-2100
    CrossrefPubMedGoogle Scholar
  • 147 Schimmel M, Frühwald MC, Bien CG. Limbic encephalitis with LGI1 antibodies in a 14-year-old boy. Eur J Paediatr Neurol 2018; 22 (01) 190-193
    CrossrefPubMedGoogle Scholar
  • 148 Bektaş Ö, Jacobson L, Tutkak H. , et al. Epilepsy and autoimmunity in pediatric patients. Neuropediatrics 2015; 46 (01) 13-19
    PubMedGoogle Scholar
  • 149 Lin JJ, Chou IJ, Lin KL, Wang HS. Childhood refractory focal epilepsy following acute febrile encephalopathy with anti-amphiphysin antibody. Eur J Neurol 2011; 18 (06) e70
    CrossrefPubMedGoogle Scholar
  • 150 Chou IJ, Wang HS, Lin JJ. , et al; CHEESE Study Group. Limbic encephalitis in Taiwanese children and adolescence: a single center study. Pediatr Neonatol 2013; 54 (04) 246-253
    CrossrefPubMedGoogle Scholar
  • 151 Quek AM, Britton JW, McKeon A. , et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol 2012; 69 (05) 582-593
    CrossrefPubMedGoogle Scholar
  • 152 Mrabet S, Ben Achour N, Kraoua I. , et al. Anti-Ma2-encephalitis in a 2 year-old child: A newly diagnosed case and literature review. Eur J Paediatr Neurol 2015; 19 (06) 737-742
    CrossrefPubMedGoogle Scholar
  • 153 Hacohen Y, Wright S, Waters P. , et al. Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry 2013; 84 (07) 748-755
    CrossrefPubMedGoogle Scholar
  • 154 Damásio J, Leite MI, Coutinho E. , et al. Progressive encephalomyelitis with rigidity and myoclonus: the first pediatric case with glycine receptor antibodies. JAMA Neurol 2013; 70 (04) 498-501
    CrossrefPubMedGoogle Scholar
  • 155 Chan DW, Thomas T, Lim M, Ling S, Woodhall M, Vincent A. Focal status epilepticus and progressive dyskinesia: a novel phenotype for glycine receptor antibody-mediated neurological disease in children. Eur J Paediatr Neurol 2017; 21 (02) 414-417
    CrossrefPubMedGoogle Scholar
  • 156 Wuerfel E, Bien CG, Vincent A, Woodhall M, Brockmann K. Glycine receptor antibodies in a boy with focal epilepsy and episodic behavioral disorder. J Neurol Sci 2014; 343 (1-2(: 180-182
    CrossrefPubMedGoogle Scholar
  • 157 Dale RC, Merheb V, Pillai S. , et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain 2012; 135 (Pt 11): 3453-3468
    CrossrefPubMedGoogle Scholar
  • 158 Pathmanandavel K, Starling J, Merheb V. , et al. Antibodies to surface dopamine-2 receptor and N-methyl-D-aspartate receptor in the first episode of acute psychosis in children. Biol Psychiatry 2015; 77 (06) 537-547
    CrossrefPubMedGoogle Scholar